DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ Small Cell Lung Cancer Pipeline Outlook

 

Key Takeaways from the Small Cell Lung Cancer Pipeline Report

• In October 2024:- Hoffmann-La Roche- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer. The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
• In October 2024:- Merck Sharp & Dohme LLC- A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98). This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an initial safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D) followed by an efficacy evaluation.
• In October 2024:- Mirati Therapeutics Inc.- A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation. CA239-0012 is a phase 2 study of adagrasib monotherapy in which patients are randomized between two dosing regimens. The study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID without regard to food versus 400 mg BID with food) in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.
• In October 2024- Novartis Pharmaceuticals- The Drugs Controller General of India (DCGI) has granted approval for Rahika® (Capmatinib) film-coated tablet 150 and 200 mg for the treatment of adult patients with advanced/metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping mutation with condition to perform a Phase IV clinical trial in Indian patients. As recommended by DCGI, this Phase IV study has been planned to evaluate the safety and efficacy of capmatinib in treatment of adult Indian patients with advanced/metastatic NSCLC whose tumors have a MET exon 14 skipping mutation positive advanced NSCLC in any line of therapy.
• In October 2024:- Boehringer Ingelheim- This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate when taken alone. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer.
• In October 2024:- AstraZeneca- This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer.
• DelveInsight’s Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
• The leading Small Cell Lung Cancer Companies include Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
• Promising Small Cell Lung Cancer Therapies in the various stages of development include Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.

 

Stay informed about the cutting-edge advancements in Small Cell Lung Cancer treatments. Download for updates and be a part of the revolution in care @ Small Cell Lung Cancer Clinical Trials Assessment

 

Small Cell Lung Cancer Emerging Drugs Profile

• AMG 757: Amgen

AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.

 

• APG-1252: Ascentage Pharma

APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.

 

Learn more about Small Cell Lung Cancer Drugs opportunities in our groundbreaking Psoriasis Research and development projects @ Small Cell Lung Cancer Unmet Needs

 

Small Cell Lung Cancer Companies

Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.

 

Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

 

Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

 

Discover the latest advancements in Small Cell Lung Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Small Cell Lung Cancer Companies- Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
• Small Cell Lung Cancer Therapies- Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.

 

For a detailed overview of our latest research findings and future plans, read the full details of Small Cell Lung Cancer Pipeline on our website @ Small Cell Lung Cancer Emerging Drugs and Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Small Cell Lung Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Pembrolizumab: Merck & Co
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Dostarlimab: GlaxoSmithKline
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. AMG 757: Amgen
17. Drug profiles in the detailed report…..
18. Preclinical/Discovery Stage Products
19. S 055746: Vernalis
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Small Cell Lung Cancer Key Companies
23. Small Cell Lung Cancer Key Products
24. Small Cell Lung Cancer- Unmet Needs
25. Small Cell Lung Cancer- Market Drivers and Barriers
26. Small Cell Lung Cancer- Future Perspectives and Conclusion
27. Small Cell Lung Cancer Analyst Views
28. Small Cell Lung Cancer Key Companies
29. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/